Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen

Molecular Cancer Therapeutics

Volumn 11, Issue 4, 2012, Pages 805-816

  Houtman, René ^a   De Leeuw, Renée ^b   Rondaij, Mariska ^b   Melchers, Diana ^a   Verwoerd, Desiree ^b   Ruijtenbeek, Rob ^a   Martens, John W M ^c   Neefjes, Jacques ^b   Michalides, Rob ^b  

^a R and D   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; SERINE; TAMOXIFEN;

ARTICLE; BREAST TUMOR; COREGULATOR PEPTIDE ARRAY; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; HUMANS; MICROARRAY ANALYSIS; OSTEOSARCOMA; PHOSPHORYLATION; SERINE; TAMOXIFEN; TRANSFECTION;

EID: 84862749595     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0855     Document Type: Article

References (43)

1. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-44. (Pubitemid 30649811)
2. Liu J, Knappenberger KS, Kack H, Andersson G, Nilsson E, Dartsch C, et al. A homogeneous in vitro functional assay for estrogen receptors: coactivator recruitment. Mol Endocrinol 2003;17:346-55. (Pubitemid 36315629)
3. Stenoien DL, Nye AC, Mancini MG, Patel K, Dutertre M, O'Malley BW, et al. Ligand-mediated assembly and real-time cellular dynamics of estrogen receptor alpha-coactivator complexes in living cells. Mol Cell Biol 2001;21:4404-12. (Pubitemid 32565321)
4. Chang C, Norris JD, Gron H, Paige LA, Hamilton PT, Kenan DJ, et al. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol Cell Biol 1999;19:8226-39. (Pubitemid 30414017)
5. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen- activated protein kinase. Science 1995;270:1491-4.
6. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 2006;20:3120-2.
7. Vendrell JA, Bieche I, Desmetz C, Badia E, Tozlu S, Nguyen C, et al. Molecular changes associated with the agonist activity of hydroxytamoxifen and the hyper-response to estradiol in hydroxy-tamoxifenresistant breast cancer cell lines. Endocr Relat Cancer 2005;12:75-92. (Pubitemid 40477089)
8. Cheng J, Zhang C, Shapiro DJ. A functional serine 118 phosphorylation site in estrogen receptor-alpha is required for down-regulation of gene expression by 17beta-estradiol and 4-hydroxytamoxifen. Endocrinology 2007;148:4634-41. (Pubitemid 47481539)
9. Duplessis TT, Williams CC, Hill SM, Rowan BG. Phosphorylation of estrogen receptor {alpha} at serine 118 directs recruitment of promoter complexes and gene-specific transcription. Endocrinology 2011; 152:2517-26.
10. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 1998;18:1978-84. (Pubitemid 28152646)
11. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 2004;5:597-605. (Pubitemid 38748921)
12. Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV, Fuqua SA. Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Res 2004;64:9199-208. (Pubitemid 39665536)
13. Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA, et al. P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res 2006;66:1694-701. (Pubitemid 43259954)
14. Xu J, Li Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 2003;17:1681-92. (Pubitemid 37072287)
15. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61. (Pubitemid 36395255)
16. Wu RC, Qin J, Yi P, Wong J, Tsai SY, Tsai MJ, et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell 2004;15: 937-49. (Pubitemid 39277990)
17. Bautista S, Valles H, Walker RL, Anzick S, Zeillinger R, Meltzer P, et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 1998;4:2925-9. (Pubitemid 29001463)
18. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-8. (Pubitemid 27366683)
19. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007;25: 5815-24.
20. Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van't Veer LJ, et al. PKA-induced phosphorylation of ERalpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 2011;125:1-12.
21. Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J, et al. Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol 2009;217:372-9.
22. Zwart W, Griekspoor A, Berno V, Lakeman K, Jalink K, Mancini M, et al. PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. EMBO J 2007;26:3534-44. (Pubitemid 47236876)
23. Koppen A, Houtman R, Pijnenburg D, Jeninga EH, Ruijtenbeek R, Kalkhoven E. Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor. Mol Cell Proteomics 2009;8:2212-26.
24. Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. Eur J Cancer 1980;16:1513-5.
25. van Ham SM, Tjin EP, Lillemeier BF, Gruneberg U, van Meijgaarden KE, Pastoors L, et al. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. Curr Biol 1997;7:950-7. (Pubitemid 28017072)
26. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, et al. Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA. Nature 2008:350-6.
27. Hilhorst R, Houkes L, van den Berg A, Ruijtenbeek R. Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase A. Anal Biochem 2009;387:150-61.
28. Heneweer M, Houtman R, Poortman J, Groot M, Maliepaard C, Peijnenburg A. Estrogenic effects in the immature rat uterus after dietary exposure to ethinylestradiol and zearalenone using a systems biology approach. Toxicol Sci 2007;99:303-14. (Pubitemid 47250387)
29. Larson CJ, Osburn DL, Schmitz K, Giampa L, Mong SM, Marschke K, et al. Peptide binding identifies an ERalpha conformation that generates selective activity in multiple in vitro assays. J Biomol Screen 2005;10:590-8. (Pubitemid 41306657)
30. Moras D. Structure of full-length PPARgamma-RXRalpha: a snapshot of a functional complex? Cell Metab 2009;9:8-10.
31. Metivier R, Penot G, Flouriot G, Pakdel F. Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains. Mol Endocrinol 2001;15:1953-70. (Pubitemid 33026110)
32. Zwart W, de Leeuw R, Rondaij M, Neefjes J, Mancini MA, Michalides R. The hinge region of the human estrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen. J Cell Sci 2010;123: 1253-61.
33. Chen D, Pace PE, Coombes RC, Ali S. Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol 1999;19:1002-15. (Pubitemid 29046844)
34. Cavailles V, Dauvois S, L'Horset F, Lopez G, Hoare S, Kushner PJ, et al. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J 1995;14:3741-51.
35. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-37. (Pubitemid 29019045)
36. Green KA, Carroll JS. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer 2007;7:713-22. (Pubitemid 47327416)
37. Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, et al. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol 1998;12:1605-18. (Pubitemid 30665208)
38. Dudek P, Picard D. Genomics of signaling crosstalk of estrogen receptor alpha in breast cancer cells. PLoS One 2008;3:e1859.
39. Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET, et al. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 2006;66:7334-40. (Pubitemid 44197716)
40. Bostner J, Skoog L, Fornander T, Nordenskjold B, Stal O. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res 2010;16:1624-33.
41. Zwart W, Griekspoor A, Rondaij M, Verwoerd D, Neefjes J, Michalides R. Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor alpha. Mol Cancer Ther 2007;6:1526-33. (Pubitemid 46954019)
42. Nagy L, Schwabe JW. Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci 2004;29:317-24. (Pubitemid 38968764)
43. de Leeuw R, Neefjes J, Michalides R. A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer 2011 Article ID 232435.